Insider Selling: Illumina (NASDAQ:ILMN) SVP Sells 783 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 1.3%

Illumina stock traded up $1.99 during trading on Tuesday, hitting $160.03. The company had a trading volume of 1,453,928 shares, compared to its average volume of 1,883,252. Illumina, Inc. has a 1-year low of $85.00 and a 1-year high of $177.22. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company’s 50 day simple moving average is $138.43 and its 200-day simple moving average is $133.92. The stock has a market cap of $24.21 billion, a price-to-earnings ratio of 29.10, a price-to-earnings-growth ratio of 3.04 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $0.97 EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ILMN shares. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Citigroup raised their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Royal Bank Of Canada assumed coverage on shares of Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Finally, Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and an average target price of $138.38.

Hedge Funds Weigh In On Illumina

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Capital World Investors lifted its position in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. State Street Corp lifted its position in shares of Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.